PR Newswire BiotechOriginal article
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
BPL-003Positive
AI Analysis
Summary
Eli Lilly announced the acquisition of AtaiBeckley to advance its neuroscience pipeline, with BPL-003 designed to treat treatment-resistant depression and other mental health conditions.
Outcome Details
Eli Lilly to acquire AtaiBeckley
Importance:7/10
Sentiment:
0.70
acquisitionneurosciencemental healthtreatment-resistant depressionpipeline expansion
Related Companies
Read the original article
Published by PR Newswire Biotech on July 16, 2026 10:45 AM